Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry R Smith

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Human Vaccines & Immunotherapeutics|December 4, 2014
Questionnaire for biotechs: Vical incorporatedIgor P Bilinsky, Larry R Smith
Journal of Immunological Methods|March 9, 2007
Novel microneutralization assay for HCMV using automated data collection and analysisAnna Maria Abai, Larry R Smith, Mary K Wloch
Vaccines|September 8, 2015
Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 TrialLarry R Smith, Mary K Wloch, Jennifer A Chaplin, et al.
Biologicals : Journal of the International Association of Biological Standardization|October 31, 2006
Qualification and performance characteristics of a quantitative enzyme-linked immunosorbent assay for human lgG antibodies to anthrax lethal factor antigenCheryl L Selinsky, Vanessa D Whitlow, Larry R Smith, et al.
Antimicrobial Agents and Chemotherapy|April 17, 2019
Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single- and Multiple-Ascending-Dose Study in Healthy SubjectsLaura L Kovanda, Sean M Sullivan, Larry R Smith, et al.
The Journal of Infectious Diseases|June 3, 2008
Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virusPeggy A Lalor, Richard J Webby, Jane Morrow, et al.
Plos Medicine|February 15, 2007
Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humansMatthew R Sandbulte, Gretchen S Jimenez, Adrianus C M Boon, et al.
Cancer Research|October 18, 2002
Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic miceGretchen L Eiben, Markwin P Velders, Hans Schreiber, et al.
Vaccine|June 26, 2009
Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccinesJukka Hartikka, Vesselina Bozoukova, Catherine K Yang, et al.
Vaccine|November 25, 2015
A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cellsMichael A McVoy, Ronzo Lee, Frances M Saccoccio, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Human Vaccines & Immunotherapeutics|December 4, 2014
Questionnaire for biotechs: Vical incorporatedIgor P Bilinsky, Larry R Smith
Journal of Immunological Methods|March 9, 2007
Novel microneutralization assay for HCMV using automated data collection and analysisAnna Maria Abai, Larry R Smith, Mary K Wloch
Vaccines|September 8, 2015
Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 TrialLarry R Smith, Mary K Wloch, Jennifer A Chaplin, et al.
Biologicals : Journal of the International Association of Biological Standardization|October 31, 2006
Qualification and performance characteristics of a quantitative enzyme-linked immunosorbent assay for human lgG antibodies to anthrax lethal factor antigenCheryl L Selinsky, Vanessa D Whitlow, Larry R Smith, et al.
Antimicrobial Agents and Chemotherapy|April 17, 2019
Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single- and Multiple-Ascending-Dose Study in Healthy SubjectsLaura L Kovanda, Sean M Sullivan, Larry R Smith, et al.
The Journal of Infectious Diseases|June 3, 2008
Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virusPeggy A Lalor, Richard J Webby, Jane Morrow, et al.
Plos Medicine|February 15, 2007
Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humansMatthew R Sandbulte, Gretchen S Jimenez, Adrianus C M Boon, et al.
Cancer Research|October 18, 2002
Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic miceGretchen L Eiben, Markwin P Velders, Hans Schreiber, et al.
Vaccine|June 26, 2009
Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccinesJukka Hartikka, Vesselina Bozoukova, Catherine K Yang, et al.
Vaccine|November 25, 2015
A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cellsMichael A McVoy, Ronzo Lee, Frances M Saccoccio, et al.
Pageof 3